Catalent (NYSE:CTLT) Earns Sector Perform Rating from Royal Bank of Canada

Catalent (NYSE:CTLT)‘s stock had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada in a research note issued on Thursday, Benzinga reports. They presently have a $63.50 target price on the stock. Royal Bank of Canada’s price target would suggest a potential upside of 10.34% from the company’s current price.

A number of other equities analysts have also recently commented on the stock. Barclays lifted their target price on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, June 28th. Stephens reiterated an “equal weight” rating and issued a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. Finally, StockNews.com started coverage on shares of Catalent in a research report on Monday, July 8th. They issued a “sell” rating on the stock. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Catalent has a consensus rating of “Hold” and an average target price of $55.65.

Catalent Trading Down 0.9 %

Shares of CTLT opened at $57.55 on Thursday. Catalent has a fifty-two week low of $31.80 and a fifty-two week high of $60.20. The firm has a market cap of $10.42 billion, a price-to-earnings ratio of -9.43, a PEG ratio of 2.37 and a beta of 1.16. The firm has a 50 day moving average price of $55.74 and a 200-day moving average price of $54.77. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51.

Catalent (NYSE:CTLT) last issued its earnings results on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). The business had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. As a group, equities research analysts forecast that Catalent will post -0.17 earnings per share for the current year.

Insider Activity

In other news, insider Ricky Hopson sold 1,401 shares of Catalent stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total transaction of $76,018.26. Following the sale, the insider now owns 20,617 shares of the company’s stock, valued at approximately $1,118,678.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Matti Masanovich sold 2,993 shares of Catalent stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $56.74, for a total transaction of $169,822.82. Following the sale, the chief financial officer now owns 33,871 shares of the company’s stock, valued at approximately $1,921,840.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ricky Hopson sold 1,401 shares of the business’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the sale, the insider now directly owns 20,617 shares in the company, valued at approximately $1,118,678.42. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

Several hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Catalent by 1.8% during the third quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock worth $931,909,000 after acquiring an additional 365,648 shares in the last quarter. Capital World Investors boosted its stake in Catalent by 6.1% during the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock worth $857,264,000 after acquiring an additional 1,098,474 shares in the last quarter. Nomura Holdings Inc. boosted its stake in Catalent by 149.4% during the fourth quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock worth $516,126,000 after acquiring an additional 6,881,914 shares in the last quarter. Cadian Capital Management LP boosted its stake in Catalent by 14.3% during the fourth quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock worth $272,473,000 after acquiring an additional 759,600 shares in the last quarter. Finally, Capital International Investors boosted its stake in Catalent by 1.2% during the fourth quarter. Capital International Investors now owns 2,994,467 shares of the company’s stock worth $134,541,000 after acquiring an additional 34,856 shares in the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.